Biotech of the Week: Agios Pharmaceuticals

As part of their weekly show, Biotech Banter, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso occasionally run a segment highlighting a biotech. This week's honor goes to Agios Pharmaceuticals (NASDAQ: AGIO  ) , which IPOed last year.

The company zoomed up 28% on Monday after presenting positive data on its cancer drug AG-221 at the American Association for Cancer Research over the weekend. In a small Phase 1 trial, six of seven evaluable patients with acute myeloid leukemia responded to AG-221, including three complete remissions and two complete remissions with incomplete platelet recovery. That's pretty amazing, considering these patients had already failed previous treatments.

Agios' pipeline is in the relatively early stages, with a couple of products, including AG-221, licensed to Celgene (NASDAQ: CELG  ) . To justify its $1.4 billion market cap, the drugs will have to work in later-stage trials, but so far everything looks promising.

Watch the following video for Brian's and Max's takes on Agios Pharmaceuticals.

3 stocks poised to be multibaggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multibagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2906277, ~/Articles/ArticleHandler.aspx, 9/2/2015 8:59:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,058.35 -469.68 0.00%
S&P 500 1,913.85 -58.33 0.00%
NASD 4,636.11 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 3:59 PM
AGIO $84.43 Down -1.97 +0.00%
CELG $115.46 Down -2.62 +0.00%
Celgene CAPS Rating: *****